Lymphoma Research

Lymphoma research includes advances in immunotherapy, targeted agents, and personalized treatment based on molecular subtypes.

Our Lymphoma Analysis

• September 22, 2026Nature MedicinePATHFINDER 2 (NCT05155605)

  Multi-Cancer Blood Test Reaches 60% Positive Predictive Value and 99.6% Specificity in Largest Prospective Screening Study to Date

  PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.

• August 20, 2026JAMA Oncology

  Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

  A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

• July 23, 2026JAMA OncologyMETA 10-19 First-in-Human Study (NCT06120166)

  Ultralow-Dose IL-10 CAR T Cells Drive 92% Response in Relapsed DLBCL

  Single-center, nonrandomized Phase 1 dose-exploration trial of META 10-19 — a CD19 CAR T-cell product engineered to also express interleukin-10 — delivered at ultralow cell doses to 13 heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).